Aurinia Pharmaceuticals (FRA:IKAP) Cyclically Adjusted Book per Share: €2.31 (As of Mar. 2026)


FRA:IKAP Aurinia Pharmaceuticals Inc FRA:IKAP
81 GF Score
Price €13.73
GF Value €12.31
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Cyclically Adjusted Book per Share?

Aurinia Pharmaceuticals FRA:IKAP 81 Cyclically Adjusted Book per Share is €2.31 as of Mar. 2026. GuruFocus rates FRA:IKAP with a GF Score™ of 81/100 and a GF Value™ of €12.31 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Aurinia Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €3.755. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.31 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Aurinia Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 13.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 11.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 11.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Aurinia Pharmaceuticals was 13.70% per year. The lowest was -37.60% per year. And the median was -11.70% per year.

As of today (2026-07-05), Aurinia Pharmaceuticals's current stock price is €13.725. Aurinia Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €2.31. Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 5.94.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Aurinia Pharmaceuticals was 21.62. The lowest was 0.40. And the median was 4.11.


Aurinia Pharmaceuticals  (FRA:IKAP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=13.725/2.31
=5.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Aurinia Pharmaceuticals was 21.62. The lowest was 0.40. And the median was 4.11.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Aurinia Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Aurinia Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Cyclically Adjusted Book per Share Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.36 1.49 2.00 2.22 2.13

Aurinia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.18 2.15 2.10 2.13 2.31

FRA:IKAP vs KOD, ABCL, AGIO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:IKAP
81GF Score
Aurinia Pharmaceuticals Inc FRA:IKAP
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurinia Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aurinia Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.755/132.2600*132.2600
=3.755

Current CPI (Mar. 2026) = 132.2600.

Aurinia Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.493 102.002 0.639
201609 0.462 101.765 0.600
201612 0.645 101.449 0.841
201703 1.966 102.634 2.534
201706 1.903 103.029 2.443
201709 1.675 103.345 2.144
201712 1.666 103.345 2.132
201803 1.471 105.004 1.853
201806 1.426 105.557 1.787
201809 1.259 105.636 1.576
201812 1.157 105.399 1.452
201903 1.346 106.979 1.664
201906 1.214 107.690 1.491
201909 1.192 107.611 1.465
201912 2.404 107.769 2.950
202003 2.119 107.927 2.597
202006 1.883 108.401 2.297
202009 2.678 108.164 3.275
202012 2.645 108.559 3.222
202103 2.427 110.298 2.910
202106 2.148 111.720 2.543
202109 1.956 112.905 2.291
202112 2.994 113.774 3.480
202203 2.871 117.646 3.228
202206 2.825 120.806 3.093
202209 3.009 120.648 3.299
202212 2.690 120.964 2.941
202303 2.549 122.702 2.748
202306 2.526 124.203 2.690
202309 2.557 125.230 2.701
202312 2.410 125.072 2.548
202403 2.302 126.258 2.411
202406 2.369 127.522 2.457
202409 2.443 127.285 2.538
202412 2.559 127.364 2.657
202503 2.352 129.181 2.408
202506 2.191 129.892 2.231
202509 2.364 130.290 2.400
202512 3.752 130.370 3.806
202603 3.755 132.260 3.755

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €2.31 mean?
Aurinia Pharmaceuticals (FRA:IKAP) has a Cyclically Adjusted Book per Share of €2.31 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Aurinia Pharmaceuticals and its competitors.
Is Aurinia Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Aurinia Pharmaceuticals' current Cyclically Adjusted Book per Share is €2.31. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Cyclically Adjusted Book per Share compare to KOD and ABCL?
Aurinia Pharmaceuticals' Cyclically Adjusted Book per Share of €2.31 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Cyclically Adjusted Book per Share is €2.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (FRA:IKAP) is currently considered Modestly Overvalued. The stock's GF Value™ is €12.31, compared to a current price of €13.73 — trading 11.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is €2.31. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Aurinia Pharmaceuticals (FRA:IKAP), the current Cyclically Adjusted Book per Share is €2.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (FRA:IKAP) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of €13.73 is trading 11.5% above its estimated GF Value™ of €12.31. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for FRA:IKAP:

  • Cyclically Adjusted Book per Share: €2.31
  • GF Value™: €12.31 vs. price of €13.73 (11.5% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the FRA:IKAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurinia Pharmaceuticals Business Description

Other Exchanges AUPH:USAIKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score

Get the complete analysis for FRA:IKAP

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.73
Price
€12.31
GF Value